Subscribe Us

header ads

Recents

header ads

Genomic Biomarker Market Size At Around US$ 8.6 Bn In 2030

The genomic biomarker market would grow at a CAGR of 7.46% over the predicted time frame. The market is expected to increase in value from US$ 4.84 Bn in 2022 to US$ 8.6 Bn in 2030.

Genomic Biomarker Market Size 2022 To 2030

The on genomic biomarker Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2231

Report Scope of the Genomic Biomarker Market

Report Coverage Details
Market Size in 2022

USD 4.84 Billion

Market Size by 2030

USD 8.6 Billion

Growth Rate from 2022 to 2030 CAGR of 7.46%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Type, Disease Indication, End-User, and Geography
Companies Mentioned Almac Group, Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, US Biomarkers Inc., Roche Diagnostics, Myriad Genetics, Bio-Rad Laboratories

A recent report provides crucial insights along with application based and forecast information in the Global Genomic biomarker Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Genomic biomarker market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Genomic biomarker market are included as given below:

Market Segments

By Type 

  • Predictive Biomarkers
  • Prognostic Biomarkers

By Disease Indication

  • Oncology
  • Cardiovascular Diseases 
  • Neurological Diseases
  • Renal Disorders
  • Others

By End-User 

  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Report Objectives

  • To define, describe, and forecast the global genomic biomarker market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the genomic biomarker market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genomic Biomarker Market 

5.1. COVID-19 Landscape: Genomic Biomarker Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genomic Biomarker Market, By Type

8.1. Genomic Biomarker Market, by Type, 2022-2030

8.1.1 Predictive Biomarkers

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Prognostic Biomarkers

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Genomic Biomarker Market, By Disease Indication

9.1. Genomic Biomarker Market, by Disease Indication, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cardiovascular Diseases

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Neurological Diseases

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Renal Disorders

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Genomic Biomarker Market, By End-User 

10.1. Genomic Biomarker Market, by End-User, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostic Centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Genomic Biomarker Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.3. Market Revenue and Forecast, by End-User (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-User (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-User (2017-2030)

Chapter 12. Company Profiles

12.1. Almac Group

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Cancer Genetics Inc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Eurofins Scientific

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Thermo Fisher Scientific Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Aepodia SA

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Epigenomics AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. US Biomarkers Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Roche Diagnostics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Myriad Genetics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Bio-Rad Laboratories

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments